Aditya Birla Sun Life Quant Fund
Direct · GrowthAI Summary
Aditya Birla Sun Life Quant Fund delivered a 1Y SIP XIRR of 9.04%, well below the category average of 14.1%, indicating underperformance versus sectoral/thematic peers. Against the NIFTY 50, the fund posted a 1Y CAGR of 10.48% versus the benchmark's -2.9%, generating a strong alpha of 13.71%. However, over longer horizons the edge narrows sharply, with 3Y alpha of just 2.15% and 5Y alpha of 1.32%.
The fund shows a modest maximum drawdown of -0.23% with one drawdown event exceeding 10%, though recovery took 524 days, suggesting slow rebound from troughs. A Calmar Ratio of 0.25 in the 1Y window indicates modest risk-adjusted returns. Downside capture of 87.75% in 1Y and 96.77% over longer periods, paired with upside capture above 100%, reflects a favorable asymmetry versus the NIFTY 50.
The portfolio holds 44 stocks with a well-spread top 10, each between 3.16% and 4.68% of NAV, led by Federal Bank, Marico, and SBI. Sector exposure is diversified, with Banks at 15.3% and Pharmaceuticals at 13.2% as the largest allocations, followed by Industrial Products, Cement, and Finance. This breadth is unusually diversified for a sectoral/thematic category and reduces single-sector concentration risk.
The fund's 1Y SIP XIRR of 9.04% trails the category average of 14.1% by roughly 5 percentage points, placing it in the weaker half of sectoral/thematic peers. Calendar year returns have been inconsistent, with -4.0% in 2024, 7.46% in 2025, and 2.31% in 2026. Its quant-driven, diversified approach makes it less explosive than typical thematic peers, which explains both the lower returns and lower volatility.
This fund suits conservative investors seeking equity exposure with a quantitative, diversified strategy rather than concentrated sector bets. A horizon of at least 5 years is advisable given the long drawdown recovery period of 524 days and modest long-term alpha. Investors with moderate risk tolerance who want benchmark-beating downside protection, rather than aggressive category-leading returns, are the best fit.
- Strong 1Y alpha of 13.71% over the NIFTY 50, with the fund gaining 10.48% while the benchmark declined 2.9%
- Favorable capture asymmetry, with 1Y upside capture of 106.38% against downside capture of only 87.75%
- Diversified 44-stock portfolio with no single holding above 4.68% of NAV, limiting concentration risk
- 1Y SIP XIRR of 9.04% significantly trails the category average of 14.1%, indicating underperformance versus peers
- Long-term alpha is thin, at just 1.32% over 5Y and 0.71% over 10Y, and the 524-day drawdown recovery suggests slow rebounds
Generated on 09-09-2026, 3:35 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.44 L | 9.0% | -14.4% | 24.6% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 9.0% | 14.4% | 14.1% | -5.4% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 5.7% | 7.0% | -11.2% | 26.1% | -0.10 | -0.12 | 73% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +13.71 | 1.04 | 106.4% | 87.8% | 10.5% | -2.9% |
| 3 Years | +2.15 | 1.02 | 101.0% | 96.8% | 2.1% | 0.0% |
| 5 Years | +1.32 | 1.02 | 101.0% | 96.8% | 1.3% | 0.0% |
| 7 Years | +0.97 | 1.02 | 101.0% | 96.8% | 0.9% | 0.0% |
| 10 Years | +0.71 | 1.02 | 101.0% | 96.8% | 0.6% | 0.0% |
| 12 Years | +0.61 | 1.02 | 101.0% | 96.8% | 0.5% | 0.0% |
| 15 Years | +0.50 | 1.02 | 101.0% | 96.8% | 0.4% | 0.0% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | The Federal Bank Limited | 4.68% |
| 2 | Marico Limited | 3.83% |
| 3 | State Bank of India | 3.77% |
| 4 | Apollo Hospitals Enterprise Limited | 3.75% |
| 5 | Ashok Leyland Limited | 3.74% |
| 6 | Grasim Industries Limited | 3.67% |
| 7 | Sun Pharmaceutical Industries Limited | 3.34% |
| 8 | Torrent Pharmaceuticals Limited | 3.32% |
| 9 | Bharti Airtel Limited | 3.27% |
| 10 | Laurus Labs Limited | 3.16% |